Dr. Reddy's Laboratories Announces First-to-Market Launch of Generic Bosutinib Tablets in the US

Dr. Reddy's Laboratories has announced the first-to-market launch of Bosutinib Tablets 400mg in the United States. This generic equivalent of Bosulif® was developed in collaboration with MSN Laboratories, with Dr. Reddy's holding exclusive marketing rights. The launch expands Dr. Reddy's oncology portfolio and aims to improve patient access to affordable medications. Bosutinib Tablets (400mg) was a first-to-file product, making it eligible for 180-days of generic drug exclusivity in the U.S. The Bosulif® brand had U.S. sales of approximately $253.8 million for the 12-month period ending April 2026. This launch underscores Dr. Reddy's commitment to timely market entry for critical therapies and strengthening its oncology offerings. MSN Laboratories provided the development and manufacturing expertise for the product.